COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Company Data

Name COMPASS PATHWAYS PLC ADR

Company COMPASS Pathways plc

Symbol CMPS

Website https://compasspathways.com

Primary Exchange

NASDAQ

WKN A2QCDR

ISIN US20451W1018

Asset Class Depository Receipt

Sector Healthcare

Industry Medical - Care Facilities

CEO Kabir Kumar Nath

Market Capitalization 400 Mio

Country United Kingdom

Currency USD

Employees 0,2 T

Address 33 Broadwick Street, W1F 0DQ London

IPO Date 2020-09-18

Ticker Symbols

Name	Symbol
Frankfurt	5Y6.F
NASDAQ	CMPS

More Shares

Investors who hold COMPASS PATHWAYS PLC ADR also have the following shares in their portfolio:

7C SOLARPARKEN AG Share

ALLIANZ AG Share

APPLE INC Share

BERKSHIRE HATHAWAY INC - CLASS B Share

iShares € High Yield Corp Bond UCITS ETF ETF

ISHARES MSCI WORLD (ACC) ETF

MCDONALDS CORP Share

MICROSOFT CORP Share

MÜNCHENER RÜCK AG Share

PERSHING SQUARE TONTINE HOLDINGS, LTDA Share

REALTY INCOME CORP Share

ROKU INC - CLASS A Share

Shanghai Jinqiao Export Processing Zone Development Co.,Ltd Share

TESLA INC Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog